Progress, Potential, and Possibilities Podcast / Show

Send us a textSteve Blank is an Adjunct Professor at Stanford and Co-Founder of the Gordian Knot Center for National Security Innovation (https://gordianknot.stanford.edu/people/steve-blank). He has been described as the Father of Modern Entrepreneurship.Credited with launching the Lean Startup movement and the curriculums for the National Science Foundation Innovation Corps and Hacking for Defense and Diplomacy, Steve has changed how startups are built; how entrepreneurship is taught; how science is commercialized, and how companies and the government innovate.Steve is the author of The Four Steps to the Epiphany and The Startup Owner’s Manual which revolutionized how startups were built. His Harvard Business Review cover story redefined how large companies can innovate at speed.Steve blogs at www.steveblank.com#SteveBlank #NationalSecurity #DepartmentOfDefense #DoD #Entrepreneuship #LeanStartup #NationalScienceFoundation #InnovationCorps #HackingForDefense #IntelligenceCommunity #SpaceX #ElonMusk #DefenseInnovationUnit #VannevarBush #VentureCapital  #PrimeContractors #LockheedMartin #Boeing #GeneralDynamics  #Raytheon #NorthropGrumman #Anduril #Palantir #Stanford #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textProfessor Carlos Duarte, Ph.D. is Distinguished Professor, Marine Science, and Executive Director, Coral Research & Development Accelerator Platform ( CORDAP - https://cordap.org/ ), Biological and Environmental Science and Engineering Division, King Abdullah University of Science and Technology ( KAUST - https://www.kaust.edu.sa/en/study/faculty/carlos-duarte ), in Saudi Arabia, as well as Chief Scientist of Oceans2050, OceanUS, and E1Series.  Prior to these roles Professor Duarte was Research Professor with the Spanish National Research Council (CSIC) and Director of the Oceans Institute at The University of Western Australia. He also holds honorary positions at the Arctic Research Center in Aarhus University, Denmark and the Oceans Institute at The University of Western Australia. Professor Duarte’s research focuses on understanding the effects of global change in marine ecosystems and developing nature-based solutions to global challenges, including climate change, and developing evidence-based strategies to rebuild the abundance of marine life by 2050.  Building on his research showing mangroves, seagrasses and salt-marshes to be globally-relevant carbon sinks, Professor Duarte developed, working with different UN agencies, the concept of Blue Carbon, as a nature-based solution to climate change, which has catalyzed their global conservation and restoration.  For the past years, Professor Duarte has also lead efforts to quantify the global role and importance of algal forests.  He has conducted research across all continents and oceans, spanning most of the marine ecosystem types, from inland to near-shore and the deep sea and from microbes to whales, and has a particular focus on the role of seaweed aquaculture as a sustainable solution for multiple challenges. Professor Duarte led the Malaspina 2010 Expedition, including over 700 scientists from 38 institutions from across 18 nations, that sailed the world’s oceans to examine the impacts of global change on ocean ecosystems and explore deep-sea biodiversity. Professor Duarte served as President of the American Society of Limnology and Oceanography between 2007 and 2010. He has published more than 950 scientific papers a and has been ranked within the top 1% Highly-Cited Scientist by Thompson Reuters in all assessments of this rank, as was ranked as the top marine biologist in the world, and recently, the 12th most influential climate scientist in the world (Reuters). He has received many honors, including the G. Evelyn Hutchinson Award from the American Society of Limnology and Oceanography in 2001, the National Science Award of Spain (2007), and the I. Vernadsky Medal of the European Geophysical Union. the Prix d’Excellence by the International Council for the Exploration of the Seas (ICES, 2011), the Carlo Heip award for excellent in Marine Biodiversity (2018), and the Ramon Margalef Ecology Award (2019), and the BBVA Foundation Frontiers of Knowledge Award in Ecology and Conservation Biology (2020).  Professor Duarte earned a bachelor's degree in environmental biology from Autonomous University of Madrid, Spain  and obtained a Ph.D. in limnology from McGill University#Corals #Oceans #Seagrass #BlueCarbon #BlueEconomy #Mangroves #Reefs #KAUST #ClimateChange #CarbonCapture #CarlosDuarte #Aquaculture #SaltwaterAgriculture #KingAbdullahUniversityOfScienceAndTechnology #KSA #SaudiArabia #RedSea #Bioprospecting #Genomics #CraigVenter #CarbonSink #Environment #Biodiversity #COP16 #Limnology  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. James L. Madara, MD, is CEO and Executive Vice President of the American Medical Association ( https://www.ama-assn.org/about/authors-news-leadership-viewpoints/james-l-madara-md ), the United States' largest physician organization. He also holds the academic title of adjunct professor of pathology at Northwestern University ( https://www.pathology.northwestern.edu/Faculty/profile.html?xid=24099 ).Since taking the reins of the AMA in 2011, Dr. Madara has helped sculpt the organization’s visionary long-term strategic plan. He also serves as Chairman of Health2047 Inc. ( https://health2047.com/ ), the wholly-owned innovation subsidiary of the AMA, created to overcome systemic dysfunction in U.S. health care and located in Silicon Valley. Working closely with the AMA, Health2047 finds, forms and scales transformative health care spinout companies in four fields: chronic care, data utility, radical productivity and health care value. Several companies have been launched to date.Prior to the AMA, Dr. Madara spent the first 22 years of his career at Harvard Medical School, receiving both clinical and research training, serving as a tenured professor, and as director of the NIH-sponsored Harvard Digestive Diseases Center. Following five years as chair of pathology and laboratory medicine at Emory University, Dr. Madara served as dean of both biology and medicine, and then as CEO of the University of Chicago Medical Center, bringing together the university’s biomedical research, teaching and clinical activities. While there he oversaw the renewal of the institution’s biomedical campus and engineered significant new affiliations with community hospitals, teaching hospital systems, community clinics and national research organizations.Dr. Madara also served as senior advisor with Leavitt Partners, an innovative health care consulting and private-equity firm founded by former Health and Human Services Secretary Mike Leavitt.Having published more than 200 original papers and chapters, Dr. Madara has served as editor-in-chief of the American Journal of Pathology and as president of the American Board of Pathology.In addition to Modern Healthcare consistently naming him as one of the nation’s 50 most influential physician executives, as well as one of the nation’s 100 most influential people in health care, Dr. Madara has been recognized with several national and international awards. These include the prestigious MERIT Award from the National Institutes of Health, the Davenport Award for lifetime achievement in gastrointestinal disease from the American Physiological Society, and the Mentoring Award for lifetime achievement from the American Gastroenterological Society.Dr. Madara is an elected member of both the American Society of Clinical Investigation and the Association of American Physicians. He also co-chairs the Value Incentives & Systems Action Collaborative of the National Academy of Medicine (NAM), and is a member of NAM’s Leadership Consortium for Value & Science-Driven Health Care.#JamesMadara #AmericanMedicalAssociation #AMA #Physicians #Pathology #IntestinalEpithelialPathobiology #MedicalSchool #MedicalEducation #HealthEquity #UniversityOfChicago #SocialDeterminantsOfHealth  #NorthwesternUniversity #Health2047 #VentureCapital #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Amal Al-Maani, MD is Director General for Diseases Surveillance and Control at the Ministry of Health of Oman ( https://moh.gov.om/en/hospitals-directorates/directorates-and-centers-at-hq/directorate-general-for-disease-surveillance-and-control/ ), senior consultant in pediatric infectious diseases in the Sultanate, and is the focal point for the Global Antimicrobial Resistance (AMR) Surveillance System (GLASS) and is responsible for Oman national surveillance system for AMR (OMASS) and the national Infection Prevention and Control (IPC) program. Dr. Al-Maani completed her medical degree from Sultan Qaboos University, Oman and passed the London School diploma in tropical Medicine and Hygiene (DTM&H) during her internship period. Followed by her postgraduate training at the University of Toronto, she achieved her fellowship in pediatric infectious diseases from the Royal College of Physicians and Surgeons, Canada. She has the Certificate In Infection Control from the Certification Board of Infection Control & Epidemiology, a certificate in global health from Dalla Lana School of Public Health the Centre for International Health in the University of Toronto (UFT), and the Patient Safety & Quality Improvement certificate from the center for patient safety in UFT.Dr. Al-Maani has participated in many national and International Conferences and presented many papers. She received Dr Susan King Award at the Canadian AMMI conference 2011 and in 2021 the WHA Sasakawa health development award for her work in AMR and IPC. She published many papers in the field of infectious diseases and infection control with a focus on Antimicrobial resistance and emerging resistant pathogens. She had been a co-author in multiple positional statements for the International Society for Infectious Diseases (ISID) group in infection control, including most recently about the Global Antimicrobial Stewardship with a Focus on Low- and Middle-Income Countries and on the Prevention of Clostridioides.#AntimicrobialResistance #AMR #AmalAlMaani #DiseasesSurveillance #MinistryOfHealth #Oman #SultanQaboosUniversity #WHO #WorldHealthOrganization #OneHealth #Antibiotics #Vaccines #TropicalMedicine #Hygiene #VancomycinResistantEnterococcus #MethicillinResistantStaphylococcus #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textMichael J. Burton is the CEO of the Diabetes Research Institute Foundation ( https://diabetesresearch.org/ ), a philanthropic organization which funds the Diabetes Research Institute, one of the largest and most comprehensive research centers dedicated to curing diabetes.A passionate nonprofit executive, Michael has more than 30 years of experience in leading high-impact philanthropic programs and cultivating strategic relationships to secure transformative funding. Prior to assuming the role of CEO at DRIF, Michael advanced the missions of some of the nation’s most dynamic and trusted institutions including Princeton University, The Pew Charitable Trusts and the American Association for Cancer Research (AACR).Michael’s accomplished nonprofit career includes significant contributions in the advancement of cancer research and care, most recently as President and CEO of Gateway for Cancer Research, a Chicago-based nonprofit engaged in funding early phase clinical research, where he began his tenure as Chief Development Officer. Prior to that, Michael served as Chief Development Officer and Executive Director of the Foundation at the AACR, the nation’s oldest and largest organization dedicated to the prevention and cure of all cancers. Michael’s 15 years of experience in the oncology sector also includes leading the development program at Fox Chase Cancer Center as Senior Vice President and Chief Development Officer.Before working in the field of oncology, Michael had a distinguished career in higher education, most notably at the University of Pennsylvania, where he served as Special Assistant to the President during the tenure of Judith Rodin, the first female president of an Ivy League institution; and at Temple University, where he held the title of Assistant Dean and lead the development program at the Fox School of Business. Before entering higher education, Michael served as Legislative and Press Assistant to the late Congressman Tom Lantos, the only survivor of the Holocaust ever elected to Congress. Michael is a graduate of the University of Pennsylvania, where he earned a Bachelor’s degree in Communications and a Master’s degree in Public Administration. Prof. Dr. Matthias von Herrath, MD is the Scientific Director of the Diabetes Research Institute (DRI) and Stacy Joy Goodman Chair at the University of Miami School of Medicine ( https://med.miami.edu/faculty/matthias-georg-von-herrath ) where he is leading the DRI mission to conduct and accelerate research to delay, prevent and ultimately find a cure for type 1 diabetes.  He is widely recognized for his groundbreaking work in understanding the molecular mechanisms of T1D, an autoimmune disease in which the body’s immune system attacks and destroys insulin-producing beta cells in the pancreas, and developing novel therapies for this disease. Prof. Dr. von Herrath served as a Professor and Director for the Type 1 Diabetes Research Center at La Jolla Institute for Allergy and Immunology, and also currently serves as Vice President and Senior Medical Officer at Novo Nordisk, a global healthcare company, where he is responsible for overseeing the company’s research and development efforts in diabetes care.Prof. Dr. von Herrath earned his medical degree in 1988 from Freiburg Medical School, where he also completed a Ph.D. equivalent thesis on biochemistry. His postdoctoral training included an intensive care residency at Diakonie Hospital, Freiburg.#DiabetesResearchInstituteFoundation #T1D #Insulin #IsletCellTransplant #Regeneration #Immunomodulation #Immunoregulation #Autoimmune #UniversityOfMiami #Philanthropy #NovoNordisk #Instacart  #ProgressPotentialAndPossibilities #IraPastor #PodcSupport the show

Send us a textDr. Legena Henry, Ph.D. is a Lecturer for Renewable Energy at University of the West Indies, Cave Hill Campus, Barbados ( https://www.cavehill.uwi.edu/fst/cmp/faculty-and-staff/academic-staff/physics/legena-henry.aspx ) with research specializing in Renewable Energy, Ocean Engineering Analysis, Ocean Wave Statistics, Marine Hydrodynamics, and Applied Mechanics. Dr. Henry is also the CEO and Founder of Rum and Sargassum Inc. ( https://rumandsargassum.com/ ), a novel transportation biofuel company in Barbados where her research has been translated and focuses on sustainably generating usable power output from natural resources of the Caribbean Sea, such as Sargassum seaweed and ocean waves.Dr. Henry completed her B.Sc. in Mechanical Engineering at Howard University, her M.Sc. in Ocean Engineering at the Center for Ocean Engineering at Massachusetts Institute of Technology (MIT), and completed her Ph.D. research in mechanical engineering at the University of the West Indies, St Augustine campus. Dr. Henry also currently serves on the MIT Educational Council. Important Episode Link - Experimental Evidence on the Use of Biomethane from Rum Distillery Waste and Sargassum Seaweed as an Alternative Fuel for Transportation in Barbados – 2021 – Interamerican Development Bank -https://publications.iadb.org/en/experimental-evidence-use-biomethane-rum-distillery-waste-and-sargassum-seaweed-alternative-fuel#LegenaHenry #Sargassum #Biofuel #Biomethane #CNG #CompressedNaturalGas #Rum #RenewableEnergy #UniversityOfTheWestIndies #Barbados #PrimeMinister #MiaMottley  #OceanEngineering #WaveStatistics #MarineHydrodynamics #AppliedMechanics  #Nature #Biodiversity #Environment #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textLinda Jiang is Head of Strategy and Government Partnerships, Healthcare, at Lyft ( https://www.lyft.com/healthcare ), where she’s responsible for accelerating the growth of the business, driving public sector strategy, and partnering with policymakers and regulators to bring access to the rideshare service to millions of people who need it for healthcare access.Previously, Linda was an early growth operator at healthcare startups, leading strategy for Modern Fertility and consumer marketing for Color Genomics. Linda began her career as a management consultant at PwC, with clients including academic medical centers, top integrated healthcare systems, medical device companies, and big box retailers, and also had a role in corporate strategy at Twitter. She holds a Master of Public Health (MPH) and a Bachelor of Science, Neuroscience and Behavioral Biology from Emory University.#Lyft #RideShare #NonEmergencyMedicalTransportation #SocialDeterminantsOfHealth #Health #Wellbeing #MedicareAdvantage #Medicaid #MaternalHealth #AgingInPlace #Loneliness #Isolation #SocialConnection #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textMichael Demurjian is CEO And Chairman of Aspargo Labs ( https://aspargolabs.com/ ), which he co-founded in 2019, which is a distinguished pharmaceutical and med-tech company committed to developing innovative oral spray formulations and drug delivery systems.Mr. Demurjian brings extensive experience across finance, manufacturing, sales & marketing, logistics, and general management. He has experience in taking companies public, raising funds in public and private markets with both retail and institutional investors. Prior to Aspargo Labs, Mr. Demurjian served as COO, CFO and member of the Board of Directors of Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. At Tyme, Mr. Demurjian was instrumental in raising over 50 million dollars and obtaining a public listing on NASDAQ. He also served as CEO of Luminant Biosciences, an oncology research company studying metabolic pathways to destroying cancer cells.Throughout his career, Mr. Demurjian has successfully completed strategic transactions with G.E., Stryker, Black & Decker Corp., and Crane Cams. Mr. Demurjian currently sits on the Board of Directors of the Susan G. Komen Foundation, the NYU board of advisors and has served in the past on the Board of Directors of Luminant Bio., Mikronite Tech & KCC. #Aspargo #MichaelDemurjian #DrugFormulation #PatientCompliance #LiquidOralSuspensions #Bioavailability #Pharmacokinetics #Pharamcodynamics #Pharmacology #Adherence #Sildenafil #Dimenhydrante #Statins #Metformin #PotassiumIodide #Antiemetics #Dysphagia #MeteredDose #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Päivi Sillanaukee, MD, Ph.D. is Special Envoy for Health and Wellbeing, Ministry of Social Affairs and Health Finland ( https://stm.fi/en/rdi-growth-programme-for-health-and-wellbeing ).Dr. Sillanaukee has over 20 years of experience at highest civil servant administrative positions, both from government, including roles as Director General at Ministry of Social Affairs and Health, Ambassador for Health and Wellbeing at the Ministry for Foreign Affairs, as well as various additional roles in the public sector at the Municipalities and Special Health care district levels.Actively participating also in Global Health, Dr. Sillanaukee has chaired and facilitated global multisectoral, multi-partner Health Security collaborations, facilitating capacity building at the country level. She served as Vice chair and member of WHO Executive Board, as Executive President for WHO/Europe Regional Committee, Member of Women in Global Health advocating for Gender Equity in Health, a member of Global Pulse Finland’s health sector advisory board, as Member of Board of Directors, Healthcare Information and Management Systems Society (HIMSS) and Member of the Inaugural Board of Digital Health & AI Research Collaborative (I-DAIR).Dr. Sillanaukee has also served as the co-chair of the Alliance for Health Security Cooperation (AHSC) and a member of the Steering Group of the Global Health Security Agenda.Dr. Sillanaukee is skilled in Health Care and Social Affairs management, Health and social service management, Health Security, Universal Health Coverage, Integrated care, Communicable & Noncommunicable diseases, Government, Management, Health Technology & innovation, Entrepreneurship, Quality Management, Interpersonal Skills, Non-profit and for profit Boards. Dr. Sillanaukee graduated with an MD, PhD, and eMBA from University of Tampere, specialization for Public Health Management, and an Honorary Doctor from University of Helsinki Faculty of Medicine.  She also studied humanities and cultural sciences in University of Jyväskylä.#PaiviSillanaukee #Finland #Healthcare #Ambassador #ForeignAffairs #SocialAffairs #HealthSecurity #UniversalHealthCoverage #IntegratedCare #CommunicableDiseases  #Wellbeing  #NoncommunicableDiseases #AgingInPlace #OneHealth #SilverEconomy #HealthTechnology #Entrepreneurship #QualityManagement #HIMSS  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Tina Ipe, MD, MPH is Chief Executive Officer at Regen Med Clinic ( https://www.regenmed.vip/ ), a medical practice which provides multi-specialty infusions, cutting-edge treatments such as therapeutic apheresis (plasmapheresis and collections), as well as novel aesthetic treatments, for patients with a variety chronic illnesses. Dr. Ipe is a board-certified physician and clinical researcher. Before entering private practice, she was Chief Medical Officer at the Oklahoma Blood Institute, Associate Medical Director at Houston Methodist Hospital, and  Division Director at University of Arkansas for Medical Sciences (UAMS). She is an expert in the fields of blood disorders, immunology, therapeutic apheresis, blood banking, and transfusion medicine. She has published more than 50 peer-reviewed manuscripts and book chapters.Dr. Ipe received her medical degree from the Medical College of Virginia and completed her residency in clinical pathology and fellowship in transfusion medicine at the Hospital of the University of Pennsylvania. She also has an MPH from Dartmouth.#TinaIpe #BloodDisorders #Blood #Biotherapies #Immunology #TherapeuticApheresis #BloodBanking #TransfusionMedicine #RegenerativeMedicine #TherapeuticPlasmaExchange #ConvalescentPlasma #ExtracorporealPhotopheresis #Parabiosis #Longevity #Aging #HospiceCare #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcastSupport the show